GO:0002737 negative regulation of plasmacytoid dendritic cell cytokine production: Immune Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002737 describes any process that stops, prevents, or reduces the frequency, rate, or extent of cytokine production by plasmacytoid dendritic cells (pDCs).
• pDCs are specialized immune cells that rapidly produce large amounts of type I interferons (IFN-α/β) and other cytokines upon viral or self-nucleic acid sensing.
• Negative regulation of pDC cytokine production is essential to prevent excessive inflammation and autoimmunity, and its dysregulation is linked to psoriasis, atopic dermatitis, and allergic airway inflammation.
• Key molecular brakes include A20 (TNFAIP3), SOCS proteins, CD100-plexin-B2 interactions, STING trafficking, and ANKRD22-NIK signaling.
• Experimental models for studying this process include knockout mice, point-mutant knock-in mice, reporter cell lines, and CRISPR library screens.
• EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, and library screening services to dissect these regulatory pathways.
Description
Plasmacytoid dendritic cells (pDCs) are a unique subset of dendritic cells that specialize in the rapid production of type I interferons and other cytokines in response to viral infections and endogenous nucleic acids. While this response is critical for antiviral immunity, uncontrolled pDC cytokine production can drive chronic inflammation and autoimmune diseases such as psoriasis and systemic lupus erythematosus. Therefore, negative regulation of plasmacytoid dendritic cell cytokine production, annotated as GO:0002737, represents a vital homeostatic mechanism that restrains pDC-driven inflammation. Understanding the molecular players and pathways that negatively regulate pDC cytokine output is essential for developing targeted therapies for inflammatory and autoimmune disorders. This article synthesizes current knowledge on GO:0002737, covering its definition, key genes, regulatory mechanisms, disease relevance, and experimental approaches for research.
negative regulation of plasmacytoid dendritic cell cytokine production At A Glance
| GO ID | GO:0002737 |
|---|---|
| GO term | negative regulation of plasmacytoid dendritic cell cytokine production |
| Ontology | biological_process |
| Synonym | down regulation of plasmacytoid dendritic cell cytokine production, down-regulation of plasmacytoid dendritic cell cytokine production, downregulation of plasmacytoid dendritic cell cytokine production, inhibition of plasmacytoid dendritic cell cytokine production |
| Major function | Restrains excessive cytokine production by pDCs to prevent inflammation and autoimmunity |
| Related cell type | Plasmacytoid dendritic cells (pDCs) |
| Key cytokines affected | IFN-α, IFN-β, TNF-α, IL-6, IL-12 |
| Disease relevance | Psoriasis, atopic dermatitis, allergic airway inflammation, autoimmunity |
What Is GO:0002737?
GO:0002737, negative regulation of plasmacytoid dendritic cell cytokine production, is a biological process defined as any process that stops, prevents, or reduces the frequency, rate, or extent of cytokine production by plasmacytoid dendritic cells. This includes inhibition of signaling pathways, transcriptional repression, or post-transcriptional mechanisms that limit the secretion of cytokines such as IFN-α, TNF-α, and IL-6 from pDCs.
Why Is negative regulation of plasmacytoid dendritic cell cytokine production Important in Cell Biology?
Negative regulation of pDC cytokine production is critical for maintaining immune homeostasis. pDCs are the body's primary source of type I interferons during viral infections, but excessive or prolonged cytokine release can cause tissue damage and drive autoimmune diseases such as psoriasis and lupus. Understanding the negative regulators of this process provides insights into disease pathogenesis and identifies potential therapeutic targets for inflammatory disorders.
• Prevents excessive type I interferon production that can lead to autoimmunity.
• Controls inflammation in skin diseases such as psoriasis and atopic dermatitis.
• Modulates allergic airway inflammation by regulating IFN-α production.
• Involves key negative regulators like A20, SOCS, and CD100-plexin-B2.
• Dysregulation is linked to chronic viral infections and cancer.
• Provides targets for therapeutic intervention in inflammatory diseases.
• Essential for understanding pDC biology in health and disease.
• Guides development of CRISPR-based models to study gene function.
What Happens During negative regulation of plasmacytoid dendritic cell cytokine production?
Initiation of negative feedback loops
In simple terms: After pDCs produce cytokines, the body starts to put brakes on the response to avoid damage.
Upon activation by nucleic acids, pDCs rapidly produce type I interferons and other cytokines. Negative regulation begins when sensors and signaling intermediates trigger feedback inhibitory pathways. For example, the ubiquitin-editing enzyme A20 (TNFAIP3) is induced and acts to dampen NF-κB and STAT1 signaling, reducing cytokine transcription. Similarly, SOCS proteins are upregulated and inhibit JAK/STAT pathways, limiting cytokine production.
Inhibition of signaling pathways
In simple terms: Specific molecules block the signals that tell pDCs to make more cytokines.
Negative regulators interfere with key signaling cascades. CD100-plexin-B2 interactions on pDCs inhibit their activation and cytokine production in psoriasis. STING, a cytosolic DNA sensor, can translocate to phagosomes to negatively regulate anti-fungal immunity, affecting cytokine output. ANKRD22 antagonizes NIK-mediated IL-23 production, thereby reducing pDC cytokine secretion.
Transcriptional and post-transcriptional repression
In simple terms: The cell reduces the production of cytokine proteins by turning down gene expression or degrading messages.
Negative regulation also occurs at the level of gene expression. IL-10, an anti-inflammatory cytokine, can suppress pDC cytokine production through transcriptional and post-transcriptional mechanisms. A20 directly deubiquitinates signaling molecules, affecting NF-κB and STAT1-mediated transcription of cytokines. Additionally, microRNAs and RNA-binding proteins may destabilize cytokine mRNAs, though specific pDC examples are still emerging.
Resolution of inflammation
In simple terms: The brakes ensure that the immune response winds down after the threat is gone.
Sustained negative regulation leads to resolution of inflammation. For instance, ANKRD22 promotes resolution of psoriasiform skin inflammation by reducing IL-23 production. In neonates, pDC deficiency enhances allergic airway inflammation due to reduced IFN-α, highlighting the importance of balanced pDC cytokine production. Proper negative regulation prevents chronic inflammation and tissue damage.
Key Genes Involved in GO:0002737 negative regulation of plasmacytoid dendritic cell cytokine production
The following genes and proteins are key players in the negative regulation of plasmacytoid dendritic cell cytokine production.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TNFAIP3 (A20) | Ubiquitin-editing enzyme that inhibits NF-κB and STAT1 signaling in pDCs | Knockout models show enhanced pDC cytokine production; target for autoimmune diseases |
| SOCS1 | Suppresses JAK/STAT signaling, limiting cytokine production | Studied in atopic dermatitis and inflammation models |
| SOCS3 | Inhibits cytokine signaling via JAK/STAT pathway | Potential target for modulating pDC responses |
| CD100 (SEMA4D) | Ligand for plexin-B2 that inhibits pDC activation | Implicated in psoriasis; modulation affects cytokine output |
| PLXNB2 | Receptor for CD100 mediating negative regulation of pDC cytokine production | Therapeutic target in psoriasis |
| STING (TMEM173) | Translocates to phagosomes to negatively regulate anti-fungal immunity | Role in pDC cytokine regulation during fungal infections |
| ANKRD22 | Antagonizes NIK-mediated IL-23 production, reducing pDC cytokines | Promotes resolution of psoriasiform inflammation |
| IL10 | Anti-inflammatory cytokine that suppresses pDC cytokine production | Studied for its regulatory effects on pDCs |
| NFKB1 | Transcription factor regulated by A20; controls cytokine genes | Knockout affects pDC cytokine production |
| STAT1 | Transcription factor inhibited by A20 and SOCS | Key mediator of IFN responses in pDCs |
| JAK1 | Kinase upstream of STATs; inhibited by SOCS | Target for JAK inhibitors in inflammatory diseases |
| JAK2 | Kinase involved in cytokine signaling; regulated by SOCS | Relevant to pDC cytokine production |
| NIK (MAP3K14) | Kinase that promotes IL-23 production; antagonized by ANKRD22 | Target for psoriasis therapy |
| Plexin-B2 | Receptor mediating CD100-induced inhibition | Modulates pDC activation in skin inflammation |
| TNIP1 | A20-binding protein that regulates NF-κB signaling | Potential modulator of pDC cytokine production |
| IRF7 | Master transcription factor for type I IFN production; subject to negative regulation | Central to pDC function; targets for inhibition |
| IRF5 | Transcription factor promoting cytokine production; can be negatively regulated | Associated with autoimmune diseases |
| TRAF3 | Adaptor protein that negatively regulates NF-κB and IFN pathways | Knockout leads to enhanced pDC cytokines |
How Is negative regulation of plasmacytoid dendritic cell cytokine production Regulated?
The negative regulation of pDC cytokine production is controlled by multiple layers of feedback inhibition. A20 (TNFAIP3) is a key negative regulator that deubiquitinates signaling molecules, thereby inhibiting NF-κB and STAT1-mediated cytokine transcription. SOCS proteins are induced by cytokines and inhibit JAK/STAT signaling, providing a negative feedback loop. CD100-plexin-B2 interactions deliver inhibitory signals to pDCs, limiting their activation. STING trafficking to phagosomes can also negatively regulate cytokine production in the context of fungal immunity. ANKRD22 antagonizes NIK, reducing IL-23 production and promoting resolution of inflammation. These pathways are tightly regulated to prevent excessive cytokine release.
negative regulation of plasmacytoid dendritic cell cytokine production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNFAIP3 (A20) | Psoriasis, autoimmunity | Knockout mice, point-mutant knock-in |
| CD100/PLXNB2 | Psoriasis | Knockout mice, overexpression cell lines |
| ANKRD22 | Psoriasiform skin inflammation | Knock-in mice, overexpression |
| SOCS1/3 | Atopic dermatitis | Knockout mice, reporter cell lines |
| STING | Anti-fungal immunity | Knockout mice, tagged knock-in |
Psoriasis
Psoriasis is a chronic inflammatory skin disease in which pDCs contribute to pathogenesis by producing IFN-α and other cytokines. Negative regulation of pDC cytokine production is impaired in psoriasis, leading to excessive inflammation. CD100-plexin-B2 interactions negatively regulate pDC activation, and dysregulation of this pathway is associated with psoriasis. ANKRD22 promotes resolution of psoriasiform skin inflammation by antagonizing NIK-mediated IL-23 production, highlighting the therapeutic potential of enhancing negative regulation.
Atopic dermatitis
Atopic dermatitis is an allergic skin condition characterized by chronic inflammation. Natural biomolecules targeting JAK/STAT/SOCS signaling have been explored for management, as SOCS proteins negatively regulate pDC cytokine production. Enhancing SOCS-mediated inhibition may reduce pDC-derived cytokines and alleviate atopic dermatitis symptoms.
Allergic airway inflammation
pDC deficiency in neonates enhances allergic airway inflammation via reduced production of IFN-α, indicating that pDC-derived cytokines are important for immune balance. Negative regulation of pDC cytokine production must be finely tuned; excessive inhibition may lead to allergic inflammation, while insufficient inhibition can cause autoimmunity.
Autoimmunity and chronic infections
Dysregulated pDC cytokine production is implicated in autoimmune diseases such as systemic lupus erythematosus, where excessive type I interferon drives pathogenesis. Negative regulators like A20 and SOCS are critical for preventing autoimmunity, and their dysfunction is linked to chronic inflammation. STING-mediated negative regulation also affects anti-fungal immunity, showing the broad impact of these pathways.
From negative regulation of plasmacytoid dendritic cell cytokine production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate pDC cytokine production? | Knockout mice or cell lines |
| Does a specific mutation in gene X affect its inhibitory function? | Point-mutation knock-in mice |
| How does gene X interact with signaling partners? | Tagged knock-in for co-IP |
| Can overexpression of gene X suppress pDC cytokines? | Overexpression cell lines |
| What genes are essential for negative regulation? | CRISPR library screening |
| How does gene X affect pDC development and function? | Conditional knockout mice |
How to Study the negative regulation of plasmacytoid dendritic cell cytokine production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on pDC cytokines | Identify negative regulators |
| RNA-seq | Transcriptional changes | Compare wild-type vs. knockout pDCs |
| Flow cytometry | Intracellular cytokine levels | Quantify IFN-α production |
| ELISA | Secreted cytokine concentrations | Measure pDC cytokine output |
| Co-immunoprecipitation | Protein-protein interactions | Study A20 complexes |
| Mass spectrometry | Post-translational modifications | Analyze ubiquitination |
| Reporter cell lines | Pathway activity | Screen for modulators |
| Conditional knockout mice | In vivo pDC function | Study disease models |
CRISPR knockout screens
CRISPR knockout screens can identify genes that negatively regulate pDC cytokine production. By transducing pDCs or their progenitors with a genome-wide sgRNA library and stimulating them, researchers can measure cytokine output and identify lost negative regulators. This approach has been used to uncover novel regulators of immune signaling.
RNA sequencing (RNA-seq)
RNA-seq measures transcriptomic changes in pDCs upon genetic perturbation or stimulation. It can reveal how negative regulators affect the expression of cytokine genes and signaling components. Comparing wild-type and knockout pDCs identifies pathways controlled by specific negative regulators.
Flow cytometry and cytokine assays
Flow cytometry can quantify intracellular cytokine production in pDCs at the single-cell level. ELISA and multiplex assays measure secreted cytokines such as IFN-α and TNF-α. These methods are standard for assessing the impact of negative regulators on pDC function.
Proteomics and immunoprecipitation
Proteomics and co-immunoprecipitation can identify protein interactions and post-translational modifications involved in negative regulation. For example, A20's ubiquitin-editing activity can be studied by mass spectrometry. Tagged knock-in models facilitate these analyses.
How CRISPR Can Be Used to Study GO:0002737 negative regulation of plasmacytoid dendritic cell cytokine production
Knockout
CRISPR knockout of candidate negative regulators in pDCs or mice can reveal their role in restraining cytokine production. For example, knockout of TNFAIP3 (A20) leads to enhanced NF-κB and STAT1 signaling and increased cytokine production. Knockout models are essential for validating gene function in vivo.
Point Mutation
Point mutations can dissect specific domains or residues required for negative regulation. For instance, mutating the deubiquitinase domain of A20 abolishes its inhibitory function. Point-mutant knock-in mice allow study of these effects in a physiological context.
Knock-in
Knock-in of tagged or reporter genes enables tracking and interaction studies. Tagged knock-in of STING allows visualization of its trafficking to phagosomes, where it negatively regulates immunity. Knock-in of human disease-associated variants can model their impact on pDC cytokine regulation.
Overexpression
Overexpression of negative regulators in pDC cell lines can suppress cytokine production. For example, overexpression of CD100 or plexin-B2 inhibits pDC activation. Overexpression models are useful for gain-of-function studies and drug screening.
How EDITGENE Supports negative regulation of plasmacytoid dendritic cell cytokine production Research
Researchers studying negative regulation of plasmacytoid dendritic cell cytokine production-related genes often need to determine whether a candidate gene is causally involved in restraining pDC cytokine output. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of plasmacytoid dendritic cell cytokine production research.
Frequently Asked Questions About negative regulation of plasmacytoid dendritic cell cytokine production
What is GO:0002737?
GO:0002737 is the Gene Ontology term for negative regulation of plasmacytoid dendritic cell cytokine production, describing any process that stops, prevents, or reduces the frequency, rate, or extent of cytokine production by pDCs.
What genes are involved in negative regulation of plasmacytoid dendritic cell cytokine production?
Key genes include TNFAIP3 (A20), SOCS1, SOCS3, CD100, PLXNB2, STING, ANKRD22, and IL10.
How does A20 regulate pDC cytokine production?
A20 (TNFAIP3) is a ubiquitin-editing enzyme that inhibits NF-κB and STAT1 signaling, thereby reducing cytokine transcription in pDCs.
What is the role of SOCS proteins in pDC cytokine regulation?
SOCS proteins are negative feedback regulators of JAK/STAT signaling and suppress cytokine production in pDCs.
How is CD100 involved in pDC regulation?
CD100 interacts with plexin-B2 on pDCs to deliver inhibitory signals that reduce cytokine production, and this pathway is relevant to psoriasis.
What diseases are associated with dysregulated pDC cytokine production?
Psoriasis, atopic dermatitis, allergic airway inflammation, and autoimmune diseases like lupus are associated with dysregulated pDC cytokine production.
What experimental models are used to study negative regulation of pDC cytokines?
Knockout mice, point-mutant knock-in mice, reporter cell lines, and CRISPR library screens are commonly used.
How can CRISPR screens identify negative regulators of pDC cytokines?
Genome-wide CRISPR knockout screens in pDCs followed by cytokine assays can identify genes whose loss increases cytokine production, revealing negative regulators.
What is the role of STING in pDC cytokine regulation?
STING can translocate to phagosomes to negatively regulate anti-fungal immunity, affecting cytokine production.
How does ANKRD22 affect pDC cytokine production?
ANKRD22 antagonizes NIK-mediated IL-23 production, reducing pDC cytokine secretion and promoting resolution of psoriasiform inflammation.
Conclusion
Negative regulation of plasmacytoid dendritic cell cytokine production (GO:0002737) is a critical process that prevents excessive inflammation and autoimmunity. Key regulators such as A20, SOCS proteins, CD100-plexin-B2, STING, and ANKRD22 provide multiple layers of control. Dysregulation of these pathways is linked to psoriasis, atopic dermatitis, and allergic airway inflammation. Understanding these mechanisms offers therapeutic opportunities, and CRISPR-based models are invaluable for dissecting gene function. EDITGENE provides comprehensive services to support this research.
References
- 1. Reizis B. 2019. Plasmacytoid Dendritic Cells: Development, Regulation, and Function.. Immunity 50(1):37-50 PMID: 30650380
- 2. Kopalli SR et al.. 2022. Potential Natural Biomolecules Targeting JAK/STAT/SOCS Signaling in the Management of Atopic Dermatitis.. Molecules 27(14) PMID: 35889539
- 3. Xiao C et al.. 2020. Negative regulation of dendritic cell activation in psoriasis mediated via CD100-plexin-B2.. J Pathol 250(4):409-419 PMID: 31943215
- 4. Rutz S et al.. 2016. Regulation of Interleukin-10 Expression.. Adv Exp Med Biol 941:89-116 PMID: 27734410
- 5. Duy PN et al.. 2019. Regulation of NF-κB- and STAT1-mediated plasmacytoid dendritic cell functions by A20.. PLoS One 14(9):e0222697 PMID: 31545817
- 6. Chen T et al.. 2023. The nucleotide receptor STING translocates to the phagosomes to negatively regulate anti-fungal immunity.. Immunity 56(8):1727-1742.e6 PMID: 37379835
- 7. Xia X et al.. 2024. ANKRD22 promotes resolution of psoriasiform skin inflammation by antagonizing NIK-mediated IL-23 production.. Mol Ther 32(5):1561-1577 PMID: 38454607
- 8. Wu M et al.. 2020. Plasmacytoid dendritic cell deficiency in neonates enhances allergic airway inflammation via reduced production of IFN-α.. Cell Mol Immunol 17(5):519-532 PMID: 31853001
